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ABSTRACT 
Because the response of human endothelial cells to growth factors and condition- 
ing  agents  has  broad  implications  for  our  understanding  of  wound  healing, 
angiogenesis,  and  human  atherogenesis, we  have investigated the  responses of 
these cells to the fibroblast (FGF) and epidermal growth factors (EGF), as well 
as to the protease thrombin, which has been previously shown to potentiate the 
growth  response  of other  cell  types  of FGF  and  EGF.  Because  the  vascular 
endothelial cells that form the inner lining of blood vessels may be expected to be 
exposed to  high thrombin  concentrations after trauma  or in pathological states 
associated  with  thrombosis,  they  are  of particular  interest  with  respect  to  the 
physiological role of this protease in potentiating cell proliferation. 
Our  results  indicate  that  human  vascular  endothelial cells respond  poorly to 
either  FGF  or  thrombin  alone.  In  contrast,  when  cells  are  maintained  in  the 
presence  of thrombin,  their proliferative response  to  FGF is  greatly  increased 
even  in  cultures  seeded  at  a  density  as  low  as  3  cells/mm  2.  Human  vascular 
endothelial  cells  also  respond  to  EGF  and  thrombin,  although  their  rate  of 
proliferation is much slower than when maintained  with FGF and thrombin. In 
contrast,  bovine  vascular  endothelial  cells  derived from vascular  territories  as 
diverse as the bovine heart, aortic arch, and umbilical vein respond maximally to 
FGF alone and neither respond to nor bind EGF. Furthermore, the response of 
bovine  vascular  endothelial  cells  to  FGF  was  not  potentiated  by  thrombin, 
indicating that the set of factors controlling the proliferation of vascular endothe- 
lial cells could be species-dependent. 
The  requirement  of cultured  human  vascular  endothelial  cells  for  thrombin 
could explain why the human cells, in contrast to bovine endothelial cells, are so 
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and  thrombin  one  can  develop  cultures  of  human  vascular  endothelial  cells 
capable of being passage repeatedly while maintaining a  high mitotic index. The 
stock cultures used for these studies have been passed weekly with a  split ratio of 
1 to 10 and are currently in their 30th passage. These cultures are indistinguisha- 
ble  from  earlier  passages  when  examined  for  the  presence  of  Weibel-Palade 
bodies or Factor VIII antigen.  We conclude that  the  use  of FGF  and  thrombin 
can  prevent  the  precocious senescence  observed in  most human  endothelial cell 
cultures previously described. 
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The  importance  of the  vascular endothelium  in 
thrombosis has long been  recognized (9).  How- 
ever, the mechanisms and factors controlling the 
regeneration of the endothelium after injury have 
remained poorly understood.  An obstacle to the 
study of the regenerative capacity of the endothe- 
lium has been the difficulty encountered in estab- 
lishing long-term cultures of endothelial cells and 
in maintaining these cells at a low enough density 
to study the factors controlling their proliferation 
(10, 24). 
Recently,  fibroblast  growth  factor  (FGF),  a 
mitogen  extracted from  pituitary and  brain,  has 
been found to promote the survival and prolifera- 
tion  of bovine  vascular endothelial  cells in  low 
density cultures (13,  15, 16, 20). The use of FGF 
has permitted the development of cloned lines of 
bovine endothelial cells. The development of such 
bovine cells lines, though important for our under- 
standing of endothelial cell function and metabo- 
lism, may have less clinical relevance than would 
corresponding  endothelial  cell  lines  of  human 
origin. The  use of cloned human endothelial cell 
lines could lead to the elucidation of the mitogenic 
factors  controlling  the  proliferative  response  of 
the human endothelium after denudation, but the 
development of such  cloned  cell lines has  been 
hampered  by  the  difficulties encountered  in  ob- 
taining cultures that could be passaged repeatedly 
without losing the ability to proliferate, and by the 
inability to maintain  human  vascular endothelial 
cells at a low enough cell density to permit cloning 
(10). 
The relative lack of success in maintaining hu- 
man  endothelial  cell  cultures  so  that  they  may 
grow vigorously for long periods of time (and with 
a high mitotic index) when passaged at low density 
could be explained by the use of cells derived from 
the umbilical vein. This vascular territory could be 
preprogrammed  to  senesce  rapidly  after  birth 
because of its unique  function as a  prenatal link 
between the mother and the fetus. Alternatively, 
the difficulty in culturing these cells could result 
from inadequate conditions under which they are 
maintained in vitro. Because growth factors such 
as FGF and  the epidermal growth factor (EGF) 
have been found to delay the onset of senescence 
and  terminal  differentiation of  several  types  of 
cultured cells (14,  26,  30),  and  because  the  re- 
sponse of human  endothelial cells to growth fac- 
tors  and  conditioning agents  has  broad  implica- 
tions  for  our  understanding  of  wound  healing, 
angiogenesis, and human  atherogenesis, we have 
investigated the  responses of these  cells to  both 
FGF and EGF, as well as to the protease throm- 
bin,  which  has  been  shown  to  potentiate  the 
growth responses of other cell types to FGF and 
EGF (3, 37). Since vascular endothelial cells form 
the  inner lining of blood vessels, they  could  be 
expected to encounter high thrombin  concentra- 
tions after trauma or in  pathological states asso- 
ciated with thrombosis, and are therefore of par- 
ticular interest  with  respect  to  the  physiological 
role of this protease in potentiating cell prolifera- 
tion. 
Our results indicate that human vascular endo- 
thelial cells respond poorly to FGF or to thrombin 
alone. However, when ceils are maintained in the 
presence of thrombin, their proliferative response 
to  FGF  is  greatly  increased,  even  in  cultures 
seeded  at  a  density  as  low  as  300  cells/cm  2. 
Human vascular endothelial cells also respond to 
EGF plus thrombin, although their rate of prolif- 
eration is much slower than when maintained with 
FGF plus thrombin.  These  results contrast  with 
those  obtained  with  cultures  of bovine  vascular 
endothelial cells derived from the umbilical vein, 
the fetal heart, or the aortic arch of the calf. In all 
cases, the cells responded maximally to FGF alone 
but  not  to  EGF.  Furthermore,  the  response  of 
bovine cells to FGF is not potentiated by throm- 
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controlling the proliferation of vascular endothe- 
lial cells may not be the same for all mammalian 
species, and  that  the  precocious senescence ob- 
served  with  human  endothelial cell  cultures  de- 
rived from the umbilical vein is not an invariably 
programmed event, but rather reflects the nutrient 
limitations of the  medium  in  which the cells are 
maintained. 
MATERIALS  AND  METHODS 
FGF  was  purified  from  bovine  pituitary  glands  and 
bovine brains as described in references 12 and 15. Both 
pituitary  and brain FGF yielded a single band on poly- 
acrylamide gel electrophoresis  at pH 4.5. No bands were 
observed at pH 8.5. For reasons of economy, FGF from 
the brain  was used in  the experiments reported here. 
The same results, however, could be obtained with FGF 
from pituitary. 
EGF was purified as described by Savage and Cohen 
(28) from the submaxillary  glands of adult, male, Swiss- 
Webster mice that had been given subcutaneous injec- 
tions of testosterone propionate (1  mg/animal per day) 
for 8 days.  The final preparation yielded a single  band 
on  polyacrylamide  gel electrophoresis at  pH  8.5,  and 
three amino acids,  lysine,  alanine, and phenylalanine, 
were absent from the final preparation (28). The biolog- 
ical  activity  of  the  EGF  (assayed  by  measuring  its 
potency in stimulating  DNA synthesis in human foreskin 
fibroblasts)  equaled  that  of  a  reference  preparation 
received from Dr.  Stanley  Cohen, Vanderbilt Univer- 
sity. 
Highly  purified human c~-thrombin (2,900  units/rag) 
was a generous gift from Dr. John Fenton (Division  of 
Laboratories and  Research, New York  State  Dept. of 
Health, Albany, New York). 
Tissue Culture of Endothelial Cells 
Endothelial ceils  were obtained from the heart  and 
aortic  arch of adult  cattle as previously  described (16, 
20). The endothelial cells from the bovine umbilical vein 
and human umbilical vein were obtained by collagenase 
digestion as described by Jaffe et al.  (24). Briefly, the 
human umbilical cord was washed with ethanol, the end 
was cut evenly, and the vein was cannulated. The vein 
was then perfused with phosphate-buffered  saline  (PBS) 
until  it was clear of blood and dots. It was then filled 
with  0.05%  collagenase  (Worthington  Biochemical 
Corp., Freehold, N. J.) in PBS, tied closed, and kept in 
a  37~  water bath  for  15  min.  It  was then  kneaded 
gently between fingers to help loosen the human endo- 
thelial cells, which were then harvested by passing N-2- 
hydroxyet  hylpiperazine-N'-2-ethane  sulfonic  acid 
(HEPES)-buffered  medium  199  supplemented  with 
20%  human serum through the vein, forcing the colla- 
genase solution  and the free endothelial cells out of the 
cord and into a  10-cm tissue  culture  dish. FGF (1  /zg/ 
ml) and thrombin (2/zg/ml) were then added. The plates 
were maintained at 37~  for 6 h in a humidified incuba- 
tor to allow the ceils to plate. The cells were then rinsed 
and incubated in fresh medium. Stock cultures were kept 
in  HEPES-buffered medium  199,  supplemented with 
10% human serum (lrvine Serum Co.), 100 ng/ml FGF, 
and 1 ~g/ml thrombin. The medium was changed every 
3  days for optimal growth. Tissue  culture  dishes were 
purchased  from  BioQuest,  BBL  &  Falcon  Products, 
Becton Dickinson  & Co., CockeysviUe, Md. 
Bovine umbilical  endothelial cells  were obtained by 
the  same  method, except that  the  medium  was  Dul- 
becco's  modified  Eagle's  (DME)  supplemented  with 
10%  calf  serum  (Grand  Island Biological  Co.,  Grand 
Island, N. Y.) and 100 ng/ml of FGF, without thrombin. 
The bovine aortic endothelial cells used were either 
early passages of uncloned cells or the cloned cell lines 
already  described (16, 20). The human endothelial cells 
were used between passages 3 to 15, the cultures being 
passaged every week with a split ratio of 1 to 10. 
Electron  Microscopy 
For electron microscopy, cells  were grown in  tissue 
culture dishes as previously  described, and fixed in situ 
with 2.5% glutaraldehyde-0.1 M cacodylate buffer (pH 
7.2)  for  20  min  at  room  temperature.  After  being 
washed with the same buffer, the cells were postfixed in 
2%  OsO4 in 0.1  M cacodylate (pH 7.2) for 20  min at 
room temperature, stained with 2%  uranyl  acetate in 
3%  ethanol,  dehydrated  with  ethanol,  and  finally 
embedded in Epon 812 on the plate to give a layer 1-2 
mm thick.  When the Epon had cured, the plastic  dish 
was peeled away  from the Epon and areas of interest 
were cut from the mold and glued to Epon blocks. Then 
sections were cut parallel to the monolayer, stained with 
lead citrate, and examined in a Hitachi HU-12 electron 
microscope. 
Fluorescence Microscopy 
The  presence of Factor VIII  antigen in  the human 
endothelial  cell  cultures  was  determined  by  indirect 
immunofluoreseence. Rabbit antibodies against  human 
Factor VIII  were  obtained from Behring Diagnostics, 
American Hoechst Corp., Somerville,  N. J. Fluorescein- 
labeled goat anti-rabbit IgG was obtained from Meloy 
Laboratories Inc., Springfield, Va. 
The endothelial cells were plated in  Lab-Tek  tissue 
culture  chambers (Lab-Tek Products, Div. Miles Labo- 
ratories Inc., Naperville, Ill.)  in  HEPES-buffered me- 
dium  199,  supplemented with 10% human serum, 100 
ng/ml of FGF, and 1 ~g/ml of thrombin. When the cells 
reached confluence, the  chambers were removed and 
the slides were washed for 5 rain in PBS. The cells were 
then  fixed  for  5  rain  in  ethanol:methanol  (1:1)  and 
dried. The dry ceils were rehydrated in PBS for 15 rain, 
excess  PBS  was  removed,  and  a  drop  of  1:100  or 
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or normal rabbit serum sufficient  to cover the slide was 
added.  The  slide  was  incubated  for 45  rain  at  room 
temperature and then  washed for 1 h  with PBS,  with 
four changes of buffer. The staining and washing proce- 
dure was then repeated with a  1:50  dilution of fluores- 
cein-conjugated goat anti-rabbit IgG. The washed slides 
were covered with one drop of PBS and a coverslip and 
examined in a Zeiss photomicroscope equipped with an 
epi-illumination  system and a Mercury vapor lamp with a 
440-nm filter.  Photographs were taken with Kodak Tri- 
X film. 
Bovine endothelial cells  were similarly  identified on 
the  basis  of the  presence of Factor  VIII  antigens as 
already described (16). 
Cell Growth Measurements 
BOVINE  VASCULAR  ENDOTHELIAL  CELLS;  Con- 
fluent  cultures  were  suspended  with  0.25%  trypsin. 
Trypsinization  was stopped with 30% horse serum, and 
the cell suspension was distributed in dishes containing 
5  ml of DME with  10%  calf serum so that  10,000  or 
20,000 cells were plated per 6-cm dish. After 18  h the 
medium was removed and the cells were rinsed once with 
DME and incubated in 5 ml of medium containing 10% 
calf serum and the various mitogens to be tested. FGF or 
EGF was added to the cultures every other day, throm- 
bin  every 4  days.  Triplicate  cultures were  trypsinized 
and counted with a Coulter counter every day or every 
other day,  All experiments were repeated six to seven 
times over a period of a year, with identical  results. 
HUMAN  VASCULAR  ENDOTHELIAL  CELLS;  Con- 
fluent  cultures  were  trypsinized  as  described for  the 
bovine  endothelial cells,  and  the  cell  suspension was 
distributed in  6-cm  dishes containing 5  ml of HEPES- 
buffered medium  199  with  10%  human serum so that 
10,000  cells were plated per 6-cm dish. After 18  h the 
medium was removed, the cells were rinsed once with 
HEPES-buffered medium  199,  and  5  ml  of medium 
containing 10% human serum and the various  mitogens 
to be tested were added to the cultures. FGF or EGF 
was added to the cultures every other day, and thrombin 
every 4  days.  Media were changed every week.  Cells 
were  counted  every  other  day,  as  already  described. 
All experiments were repeated six to seven times over a 
period of a year, with identical  results. 
Iodination of EGF 
The lactoperoxidase technique (32) was used to label 
the  EGF with ~2~I. The  labeled protein was separated 
from  unreacted  Na12SI by  passage  of  the  iodination 
mixture  through a Sephadex G-25 column (i  ￿  50 cm) 
equilibrated and eluted with a buffer containing 0.1  M 
phosphate (pH 7.4) and 0.15  M sodium chloride. The 
labeled EGF was stored frozen in the presence of 0.1% 
albumin.  The  specific  activity  of  the  ~zSI-EGF was 
110,000 -  230,000 cpm/ng. 
1251-EGF Binding Assay 
Confluent cultures in 6-era dishes were washed twice 
with 4-ml aliquots of binding medium which consisted of 
DME  containing 0.1%  bovine  serum  albumin  (BSA) 
10  -r  M  KI,  50  mM N,N-bis-(2-hydroxyethyl)-2-amin- 
ethanesulphonic acid  (BES)  adjusted  to  pH  6.8.  The 
cells were incubated at 37~  with 2  ml of the binding 
medium containing I251-EGF at the required concentra- 
tion.  After incubation,  unbound  radioactivity  was  re- 
moved by washing the cells four times with cold (5~ 
Tris-saline buffer at pH 7.4. To detach the cells, 2 ml of 
a 0.025% solution  of trypsin  in Tris-saline  buffer minus 
calcium  and magnesium were added to each dish, and 
the dishes were incubated at 37~  for 10 rain. A 0.2-ml 
aliquot of the cell suspension was removed for cell count- 
ing  (Coulter counter).  The  remaining contents of the 
dishes were transferred to counting vials, and the radio- 
activity  was  measured  with  a  Beckman  310  series 
gamma counter. 
RESULTS 
Characterization  of Human 
Endothelial Cells 
The  cells cultured  from  human  umbilical  vein 
show the characteristic morphology of endothelial 
cells.  When  maintained  at  confluence  for  ex- 
tended periods of time in medium containing 10% 
human serum and 1 /.tg/ml FGF, the cells become 
tightly packed but show no tendency to overlap or 
overgrow one  another  (Fig.  1).  To  confirm that 
these cells were derived from  endothelium, they 
were examined by immunofluorescent staining for 
the presence of Factor VIII antigen, reported to 
be characteristic of endothelial cells (2,  23,  25). 
Positive staining for Factor VIII  antigen was ob- 
served  in  the  perinuclear region  in  most  of the 
human  umbilical  vein  cells  (Fig.  2a).  Higher 
magnification (Fig.  2b)  reveals distinct foci indi- 
cating a vesicular localization of the antigen. With 
the exception of bovine vascular endothelial cells, 
which  exhibit  the  same  fluorescence  pattern  as 
human cells, positive staining for Factor VIII anti- 
gen  has not been observed in  any  other cultures 
examined,  including granulosa  cells,  luteal  cells, 
adrenal cortex cells, foreskin fibroblasts, vascular 
smooth muscle ceils, corneal endothelial cells, and 
corneal  or  lens  epithelial  cells.  Electron  micro- 
scope examination of the cytoplasm of the human 
endothelial cells revealed  abundant  rough  endo- 
plasmic reticulum which reflects the high secretory 
activity  of these  cells.  Also  observed  were  free 
ribosomes,  microtubules  250  ,&  in  diameter,  as 
well  as  numerous micropinocytotic vesicles 500- 
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maintained at confluence in the presence of 100 ng/ml FGF and 2/~g/ml thrombin, x  100. 
1,000/k in diameter. Small bundles of 60-70/~, 
diameter  filaments  and  100  ~  filaments  were 
observed  at  the  cell  peripheries.  Weibel-Palade 
bodies were  numerous (Fig.  3 C).  Bovine endo- 
thelial cells  derived from  either  the  aortic  arch 
(Fig. 3 A) or the umbilical vein display (Fig. 3 B) 
the same general structural features as the human 
umbilical vein endothelial cells  but do  not have 
Weibel-Palade bodies. This indicates that Weibel- 
Palade  bodies  are  not  a  universal  marker  for 
endothelial cells. 
The Effect of FGF, EGF, and Thrombin 
on the Proliferation  of Human Vascular 
Endothelial Cells 
Endothelial cells obtained by collagenase treat- 
ment  of  human  umbilical veins will  proliferate 
when cultured in HEPES-buffered medium  199 
supplemented with either FGF (1 p,g/ml) or EGF 
(100  ng/ml),  provided  the  medium  is  supple- 
mented  for  10-20%  human  serum.  The  cells, 
however,  when  cultured  in  medium  containing 
10-35%  bovine  or  fetal  bovine  serum  grow 
poorly, even in the  presence of FGF and EGF. 
The  requirement for  human serum  for  optimal 
growth of human endothelial cells is not surpris- 
ing,  for,  although  FGF  and  EGF  show  little 
species-specificity  themselves,  the  growth  re- 
sponse of any cell type is mediated by conditioning 
factors present in the serum which may be species- 
specific.  Because, for  primates,  many hormones 
are known to be effective only on cells of the same 
species from which they were isolated, it is likely 
that human endothelial cells require agents found 
only in human serum that allow them to respond 
maximally to FGF and/or EGF, 
Thrombin did not, by itself, have a pronounced 
778  ThE JOURNAL OF  CELL BIOLOGY" VOLUME 77,  1978 FIaURE 2  Immunofluorescent staining for  Factor  VIII antigen in cultured human  endothelial cells. 
Cultures grown in the presence of 100 ng/ml FGF, 2 /zg/ml thrombin, and  10% human serum were 
treated as described in reference 16. Factor VIII antiserum diluted 1:1,000. Cultures treated with normal 
rabbit antiserum at 1:100 dilution did not fluoresce. (a) x  100; (b) ￿  400. 
effect on the proliferation of vascular endothelial 
cells. Because it has been previously observed that 
thrombin is able to potentiate the response of cells 
to other growth factors, including FGF and EGF 
(37),  we  decided to  test the response of human 
endothelial cells to FGF and EGF in the presence 
and  absence  of  thrombin.  Fig.  4A  shows  the 
response of these cells to various concentrations of 
FGF with and without thrombin. It can be seen 
that thrombin acts to potentiate the effect of FGF 
such that the dose-response is displaced by more 
than two orders of magnitude. For example, the 
increase in cell  number observed  when cultures 
are  incubated with  1  ng/ml FG~F plus  1  /zg/ml 
thrombin exceeds  that  observed with  100  ng/ml 
FGF and no thrombin. Whereas thrombin alone 
induces only a  threefold increase in cell number 
after  15  days, cells incubated in the presence of 
thrombin plus FGF increase more than  100-fold 
(Fig. 4 A). Although thrombin does potentiate the 
effect  of  saturating concentrations of  FGF,  the 
most ponounced effects  of thrombin are observed 
when subsaturating doses of FGF are employed. 
As noted before, EGF effectively stimulates the 
proliferation of human vascular endothelial cells, 
although to a  lesser extent than does FGF (Fig. 
4 B). Although lower doses of EGF than of FGF 
are  required  to  induce a  proliferative response, 
the  maximal cell numbers obtained are  never so 
great as with FGF. Thrombin can be seen (Fig. 
4 B) to potentiate the response to EGF in much 
the  same  way  as with FGF, that is,  by allowing 
the cells to respond to reduced concentrations of 
the growth factor. 
When cultures of human umbilical vein endo- 
thelial cells  are  treated  with  saturating doses  of 
either FGF (1  /zg/ml) or EGF (100 ng/ml), the 
addition of thrombin does not significantly  shorten 
the  population-doubling time (Fig. 5).  This is in 
contrast to the  effect of thrombin on cells  main- 
tained with subsaturating concentrations of EGF 
or FGF (Fig. 4), and indicates that the effect of 
thrombin is to sensitize the cells  to low doses of 
mitogens rather than to affect directly the cycling 
time of the cells. 
The Effect of FGF, EGF, and Thrombin 
on the Rate of Proliferation of Bovine 
Vascular  Endothelial Cells 
We have also investigated the effect of thrombin 
on  the  growth  and  survival of  a  cloned line of 
GOSI~DDAROWICZ ET  AL.  Proliferation  of Human Vascular Endothelial Cells  779 FIGURE  3  Electron  micrographs of vascular endothelial ceils derived from (A) the adult bovine aortic 
arch, (B) the bovine umbilical vein, (C) the human umbilical vein. (A) Numerous vesicles (v)  are seen 
near the cell surface, 60-70/~ and 100/~ filaments (f) are evident, as are microtubules (m). Numerous 
ribosomes and polysomes are seen in the cytoplasm; (n), nucleus, x  25,000.  Bar, 0.5 /zm. (B) The same 
structural features can be seen as in (A).  ￿  25,000.  Bar, 0.5  /~m. (C) Numerous Weibel-Palade bodies 
(W) can be seen in the cytoplasm; other structural features are similar to those seen for adult bovine aortic 
arch (A) and the bovine umbilical vein (B).  ￿  37,000. Bar, 0.5 t~m. 
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In contrast to the human endothelial cells, growth 
of the bovine cells is not affected by EGF (Fig. 6), 
and  the  response  to  FGF  is  not  potentiated  by 
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FIGURE  4  Effect of thrombin on  the response of hu- 
man  endothelial cells to  FGF and  EGF.  10,000  cells 
were  plated  in  6-cm  dishes in  HEPES-199  with  10% 
human serum  and  maintained in  the  presence of (A) 
FGF or (B) EGF in the  presence (I-I)  or absence 
(O-II)  of thrombin (2  ~g/ml).  On  day  i5,  triplicate 
cultures were trypsinized and counted. Controls treated 
only with thrombin contained 2.2  ￿  104 cells.  Standard 
deviation did not exceed 10% of the mean. 
thrombin (Fig.  7 B).  It  should  be  noted  that the 
bovine cells are much more sensitive to FGF than 
are human cells. Bovine cells respond to FGF at 1 
ng/ml  and  reach  saturation  at  100  ng/ml.  The 
effect of thrombin on the human endothelial cells, 
therefore, is to shift the log dose response to that 
found  naturally  with  the  bovine  cells.  This  may 
represent  an  optimal  response  that  cannot  be 
improved upon by further addition of conditioning 
factors. With EGF, the human cells are responsive 
to concentrations of  1  ng/ml or greater,  and  are 
potentiated  by  the  presence  of  thrombin,  while 
the  bovine  cells  are  unresponsive  to  doses  be- 
tween 0.1 ng/ml and 100 ng/ml in the presence or 
absence of thrombin (Fig. 7 B). 
Because  the  differential  response  of  bovine 
versus  human  vascular  endothelial  cells  to  EGF 
and to the potentiating effects of thrombin could 
be due to their differing sites of origin (aortic arch 
and umbilical vein), we have compared the mito- 
genic effects of EGF and FGF on bovine vascular 
endothelial  cells  derived  from  diverse  vascular 
territories including fetal, as well as adult, bovine 
heart, aortic arch,  and umbilical vein. In no case 
were we able to obtain a  mitogenic effect of EGF, 
although the cells did respond quite  well to FGF 
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F[6URE  5  Growth rate of human endothelial cells maintained in the presence of saturating concentra- 
tions of FGF and EGF with or without thrombin. Cells were plated at 10,000 cells/6-cm dish in HEPES- 
buffered  medium  199  supplemented  with  10%  human serum.  (A) The  cells were  maintained in the 
presence  of FGF alone  ([:]-[:3),  FGF  +  thrombin  (I-l),  thrombin alone  (O+O),  or  without any 
addition (&+A). FGF was added every other day at a concentration of 1 /xg/ml.  Thrombin was added 
every 4 days at a final concentration of 2/zg/ml. The media were changed weekly ( 1' ). Standard deviation 
did not exceed 10% of the mean. (B) The cells were maintained in the presence of EGF alone (O-O), 
EGF plus thrombin (e-4,),  thrombin alone (O+O), or without any addition (&+A). EGF was added 
every other day at a final concentration of 100 ng/ml. Thrombin was added every 4 days at a final con- 
centration of 2  /zg/ml. The media were changed weekly  ( 1' ).  Standard deviation did not exceed  10% 
of the mean. 
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FIGURE  6  Growth rate of bovine endothelial ceils maintained in the presence of FGF or EGF with or 
without  thrombin.  Vascular  endothelial  cells  derived  from  the  adult  aortic  arch  (56  passages,  336 
generations) were plated at 740 cells/cm  2 in 6-cm dishes in DME supplemented with 10% calf serum (16). 
(A) The cells were maintained in the presence of FGF alone (O -  O), FGF +  thrombin (I -  I), thrombin 
alone ([]+n), or without any addition (￿9169  FGF was added every other day at a final concentration of 
100 ng/ml, and thrombin was added every 4 days at a final concentration of 2/zg/ml. Standard deviation 
did not exceed 10% of the mean. (B) Same as (A), but the cells were maintained in the presence of EGF 
alone  (0-O),  EGF  +  thrombin (I-I),  thrombin alone  (~--rq),  or without any addition  (￿9169 
EGF was added  at a final concentration of 100 ng/ml, and thrombin at 2  /xg/ml. Standard deviation did 
not exceed 10% of the mean. 
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FIGURE  7  Effect  of thrombin on  the  response of bo- 
vine  endothelial  cells  to  FGF  and  EGF.  Cells  were 
plated  at  370  eells/cm  2 in  6-cm  culture  dishes in  Dul- 
becco's modified  Eagle's medium containing  10%  calf 
serum.  FGF  (A)  and  EGF  (B)  were  added  at  the 
indicated concentrations every other day, and thrombin 
(2  tzg/ml) was added  on day 4. After 7 days, triplicate 
cultures were trypsinized and counted. Controls treated 
with thrombin alone contained 3.6  x  104 cells. Standard 
deviation did not exceed 10% of the mean. 
(Fig.  8).  Likewise,  thrombin did  not  have  any 
potentiating effect on any of the bovine cultures 
maintained in the presence of either EGF or FGF. 
In  the  experiments  described  above,  human 
cells  grown  in  human  serum  were  found to  be 
responsive  to  EGF  and  to  thrombin,  whereas 
bovine cells in bovine serum were not. To deter- 
mine whether these different responses might be 
due to differences in the sera, we have repeated 
these  experiments using human serum  with  the 
bovine cells to see if they might respond to EGF 
or thrombin under these conditions. As shown in 
Table  I,  bovine endothelial cells  maintained in 
human serum responded to  FGF and  not  at  all 
to either thrombin or EGF. 
EGF-Binding Sites in Human and Bovine 
Vascular Endothelial Cells 
The lack of responsiveness of bovine vascular 
endothelial cells to EGF could result either from 
a  constitutive defect  (lack  of  receptors  for  the 
mitogen) or  from  culture  conditions that  could 
make  the  cells  unresponsive  to  the  mitogenic 
stimulus.  An  example  of  the  latter  situation is 
found with corneal epithelial cells.  When main- 
tained in tissue culture, these cells do not respond 
to EGF, although specific EGF-receptor sites can 
be  readily detected  (19).  In contrast,  when  the 
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FIGUI~E  8  Effect of increasing concentrations of EGF and FGF on the proliferation of bovine vascular 
endothelial cells derived from the umbilical vein (A), the fetal aortic arch (B), the fetal heart (C), and the 
calf aortic arch (D). The cells were plated at 740 cells/cm  2 in a 6-cm dish in DME supplemented with calf 
serum. The vascular endothelial cells derived from the umbilical vein (A) and the fetal heart (C) were 
maintained in the presence of 2.5%  calf serum, while the endothelial cells derived from the fetal aortic 
arch (B) or the calf aortic arch (D) were maintained in the presence of 5 and 10% calf serum, respectively. 
All cell strains were in their third passage; FGF or EGF was added at  100 ng/ml every other day. Ceils 
from the umbilical vein were counted on day 7, and cells from the fetal heart, fetal aortic arch, and calf 
aortic arch were counted on day 8. The final cell densities reached in the absence of FGF or EGF for the 
cells derived from the umbilical vein and the fetal heart were 2,036 cells/cm  2 and 1,000 cells/cm  2, respec- 
tively, indicating a  nearly total dependency upon  FGF for proliferation.  With both fetal and calf aortic 
arch, the densities reached were 8,150 cells/cm  2 and 6,500 cells/cm  z. The bar shows the standard devia- 
tion. 
TABLE  I 
The Effect of Human and Calf Sera on the Response of Bovine Fetal Heart, Calf  Aortic Arch, and Umbilical 
Vein Endothelial Cells to FGF, EGF, and Thrombin 
Calf serum  Human serum 
Endothelial cells  FGF  EGF  Thrombin  FGF  I~GF  Thrombin 
Fetal heart  160 --- 9.6*  4.9 •  0.32  4.6 -  0.27  152 •  9.1  4.7 •  0.28  4.6 --- 0.28 
Calf aortic arch  221  --- 14.0  19.0 _  1.1  17.8 --- 0.9  186 --- 9.2  14.5 -  0.52  14.2 •  0.86 
Umbilical vein  197 •  13.0  2.9 -  0.17  3.2 •  0.21  198 •  12.0  2.8 --- 0.14  2.5  •  0.14 
The cells were plated at 740 cells/cm  2 in a  6-cm dish in DME supplemented with either calf or human serum. The 
vascular endothelial cells derived  from  the  umbilical vein  and  the fetal heart  (A and C) were  maintained in  the 
presence of 2.5% calf serum or 10%  human serum, and the endothelial cells derived from the calf aortic arch were 
maintained in the presence of 10% calf serum or 10%  human serum, respectively. All cell strains were in their fifth 
passage; FGF or EGF was added at  100 ng/ml, and thrombin was added  at  2  /~g/ml every other day. Triplicate 
cultures were counted on day 12. 
* Cell number x  104 •  standard error. 
cornea  is  maintained  in  organ  culture,  the  same 
cell type will  proliferate  actively when exposed to 
EGF  (19). 
When  the  specific  binding  of  EGF  to  bovine 
vascular endothelial cells derived from the bovine 
aortic arch or bovine umbilical vein was compared 
to  that of human  umbilical vein endothelial  cells, 
it was observed that the human  umbilical endothe- 
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human  or  calf serum  bound  EGF,  whereas  the 
bovine cells maintained  in the presence  of either 
human  or  calf serum  do  not  have  receptors  for 
EGF (Fig.  9).  When  the  specific binding  of 125I- 
EGF  to  endothelial  cells  derived  from  human 
umbilical vein, bovine umbilical vein, and bovine 
aortic arch was compared (Fig. 9 A), it was found 
that  only  the  human  cells  bound  labeled  EGF, 
and  the the time-course of binding to the human 
vascular  endothelial  cells was  similar to  that  ob- 
tained  for binding  of v'~I-EGF to  3T3  cells  (un- 
published  observations of K. Brown)  and  to that 
published  for NRK ceils (33)  or for human  fore- 
skin fibroblasts (5). The effect of EGF concentra- 
tion  on  binding  was  studied  by  measuring  the 
maximal binding  after  the  addition  of increasing 
quantities of ~25I-EGF to  the cells (Fig.  9 B).  No 
significant binding to the bovine endothelial cells 
was  seen  at  any  concentration  tested,  whereas 
binding to the human endothelial cells was shown 
to  be  a  saturable  process.  A  Scatchard  plot  of 
EGF-binding  to  these  cells is shown  in  Fig.  9 C. 
Half-maximal  binding  capacity  was  165  pg/10  ~ 
cells. These values are similar to those found  for 
EGF-binding to epithelial cells (17),  to 3T3  cells 
(unpublished  observations),  and  to  human  fore- 
skin fibroblast cultures  (5). These results demon- 
strate that bovine vascular endothelial cells in the 
presence  of bovine  or  human  serum  differ from 
human  umbilical  vein  endothelium  exposed  to 
human  or  bovine  serum  in  their  ability  to  bind 
EGF, and that these physiological differences are 
reflected  in  the  growth  responses  of  the  cells 
maintained  either in homologous or heterologous 
serum. 
DISCUSSION 
Our  results  demonstrate  that  by  using  FGF  and 
thrombin  one  can  develop  cultures  of  human 
vascular  endothelial  cells  capable  of  being  pas- 
saged repeatedly while maintaining a  high mitotic 
index.  The  stock  cultures  used  for  these  studies 
are passed weekly with a split ratio of 1 to 10 and 
are currently in their 30th passage. These cultures 
are  indistinguishable  from  earlier  passages  when 
examined for the presence of Weibel-Palade bod- 
ies  or  Factor  VIII antigen.  One  could  conclude 
that the use of FGF and thrombin can prevent the 
precocious  senescence  observed  in  most  human 
endothelial cell cultures previously described (10, 
24).  This  result  is  similar  to  results  obtained 
earlier with the bovine vascular endothelial cells. 
Those  cells have  been  shown  to  be  easily  main- 
b 
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FIGURE 9  Comparison of the binding of IzSI-EGF to human endothelial cells and bovine endothelial cell 
cultures.  (A) Time-course of specific I~5I-EGF binding to endothelial cells from human umbilical vein (k) 
maintained in the presence of human sera, bovine umbilical  vein (O), or bovine aortic arch-derived (@) 
endothelial cells maintained in bovine serum. 2 ml of binding medium, containing 7 ng/ml of 125I-EGF 
(60,000 cpm/ng), were added to each dish and the dishes were incubated at 37"C. At the indicated time 
intervals, the cell-bound radioactivity was determined as described in Materials and Methods. For each 
time-point,  nonspecific  binding  was  measured  in  the  presence  of 500  ng/ml  of unlabeled  EGF  and 
subtracted from the total bound. Identical results  were obtained when the endothelial cell cultures were 
maintained in the presence of heterologous sera (human cells with bovine serum and bovine ceils with 
human serum). Standard deviation did not exceed 10% of the mean. (B) Effect of I~5I-EGF concentration 
on binding to endothelial cells from human umbilical vein (A), bovine umbilical vein (O), and bovine 
aortic arch (@). Indicated concentrations of ~I-EGF (60,000 cpm/ng) in 2 ml of binding medium were 
added to dishes,  and the cell-bound radioactivity was determined after 60 rain.  Incubation is described in 
Materials and Methods. Standard deviation did not exceed 10% of the mean. (C) Scatchard  plot of binding 
data for human umbilical endothelial cells presented in Fig. 9 B. The line was fitted by a linear regression 
program without weighted factors. 
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time,  provided  FGF is  present  in  the  medium. 
Clonal lines of bovine vascular endothelial cells 
have been passaged weekly with a split ratio of 1 
to  64 for over 65  wk  (390 generations) without 
any changes in  their karyotypes  (2n  =  60)  and 
without  loss  of  differentiated  functions  as  ex- 
pressed by their contact inhibition pattern at con- 
fluence and the presence of Factor VIII antigen. 
The responses of  bovine and human vascular 
endothelial cells to mitogens have been found to 
differ.  Whereas human vascular endothelial cells 
respond to EGF as well as to FGF, bovine endo- 
thelial cells do not respond at all to EGF, even at 
concentrations as  high  as  1-10  /~g/ml  (unpub- 
lished  data).  Furthermore,  binding studies  indi- 
cate that the lack of response of the bovine endo- 
thelial cells is due to a  lack of receptor sites for 
EGF. In contrast, the response of human vascular 
endothelial cells to  EGF can be correlated  with 
the  presence of receptor sites for  that  mitogen. 
The lack of responsiveness of bovine endothelial 
cells  to  EGF is  not specific  to  a  given vascular 
territory, since it has been observed with bovine 
endothelial cell  cultures obtained from  the  um- 
bilical vein, as well as from the heart  and aortic 
arch.  Although it  may be possible that  only hu- 
man umbilical vein endothelial cells have receptor 
sites for EGF, such conclusions will have to await 
the investigation of endothelial cells derived from 
other human vascular territories such as the heart 
or aorta. 
Another  discrepancy  between  the  mitogenic 
responses of bovine and human vascular endothe- 
lial cells is that bovine cells respond optimally to 
FGF, whereas human cells require the potentiat- 
ing effect of thrombin. This demonstrates that the 
proliferation  of  endothelial cells  from  different 
species can be under the control of different sets 
of factor(s).  Likewise, endothelial cells  from dif- 
ferent  species  can  also  exhibit ~reat  differences 
when one considers their structural features. Wei- 
bel-Palade bodies, for example, which are promi- 
nent in human umbilical vein endothelium, have 
not been detected in our bovine endothelial cell 
cultures, even with cells derived from the bovine 
umbilical vein. Such a  pronounced difference be- 
tween  the  two  species  leads  us  to  believe  that 
other differences, as yet unknown, could also be 
present. Among those could be differences relat- 
ing  to  lipid  transport  or  to  hormonal receptor 
sites. 
One could argue that  human endothelial cells 
derived from the  umbilical vein are  not the  best 
human endothelial cell models, as those cells are 
derived  from  a  fetal  tissue  usually discarded  at 
birth. In late pregnancy, the earliest sign of degen- 
eration involving  the placenta always occurs in the 
umbilical  vein,  thus  resulting  in  a  diminished 
blood flow to the fetus and in cerebral damage. 
This could indicate that endothelial cells obtained 
from the umbilical vein, because they belong to a 
senescent territory,  are  preprogrammed  to  die, 
and that their requirements for proliferation could 
therefore  be  quite  different from  those  of other 
fetal or adult vascular territories. This point will, 
however,  be  difficult to  evaluate in view of the 
difficulties in obtaining human samples. However, 
if one refers to tissue of bovine origin (in which a 
comparison of the characteristics of different vas- 
cular territories can readily be done), we  cannot 
observe  any  differences  among  endothelial  cell 
cultures derived from the bovine umbilical vein, 
aortic arch, or heart in regard to their control of 
proliferation. This fact leads us to believe that the 
precocious senescence observed with human um- 
bilical vein endothelial cell cultures in vitro reflects 
the inadequacy of the medium in which the cells 
are  maintained  rather  than  a  preprogrammed 
fixed rate of mutation which leads to the death of 
the  cells.  Similar conclusions have been reached 
by others concerning the life in culture of either 
keratinocytes from  different  origins (26,  30)  or 
granulosa cell  cultures  (14),  as  the  addition  of 
EGF and/or FGF to these cultures greatly extends 
their replicative lifespan. 
The requirement for thrombin of cultured hu- 
man vascular endothelial cells could explain why 
human  cells,  in  contrast  to  bovine  endothelial 
cells, are so difficult to maintain in human tissue 
culture. Gimbrone et  al.,  for example, reported 
that  one-third of their primary human umbilical 
vein cultures did not reach confluence, and that 
inocula of  less  than  1.2  ￿  104  viable cells/cm  2 
usually failed to become established (10,  11). In 
contrast, Booyse et al. (2), as well as others (29, 
34),  have  recently  reported  that  adult  bovine 
endothelial cells  could be passaged  when seeded 
at a density as low as 4  x  102 cells/cm  2. Because 
bovine endothelial cells do not require thrombin 
to be sensitized to the  mitogenic effect of serum 
factors, one would expect that, when maintained 
in the presence of optimal concentrations of serum 
factors,  they  would  proliferate  rapidly.  In  con- 
trast, human cells require thrombin in addition to 
serum  factors.  Although  thrombin  is  a  normal 
component of serum, it is rapidly inactivated and 
is usually present in low concentration in its active 
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cells, although exposed to the same concentration 
of serum factors as bovine cells, will fail to prolif- 
erate because of inadequate thrombin concentra- 
tion. 
The ability of thrombin to stimulate cell prolif- 
eration  or  to  potentiate  the  effects  of  other 
growth-promoting  factors  is  a  relatively  recent 
addition to our knowledge concerning this enzyme 
(3, 6, 37). Although thrombin does not appear to 
be a primary mitogen for as wide a variety of cell 
types  as does  FGF or  EGF (8,  15,  18,  21),  its 
effects are of particular interest for those cell types 
that can be expected to encounter high concentra- 
tions  of  thrombin  under  physiological  circum- 
stances.  Since  vascular  endothelial  cells  are  in 
direct and continual  contact with circulating fluids, 
they  are  very likely to be influenced by fluctua- 
tions  in  the  levels  of  those  proteases,  such  as 
thrombin, that are involved in hemostasis. 
The mechanism by which thrombin potentiates 
the effect of other growth factors is unclear, but is 
probably mediated by action on the  cells them- 
selves and not by direct cleavage of the factors. 
The  observation that  thrombin can remove spe- 
cific proteins from cell surfaces (7,  31,  35)  sug- 
gests  that  the  enzyme could  act  to  expose  new 
binding or  transport sites for  the  other  growth- 
effecting molecules. Whether thrombin is internal- 
ized by endothelial cells as it is by chick embryo 
fibroblasts is not yet known (36). 
Our finding that thrombin allows cultured hu- 
man endothelial cells to respond to concentrations 
of FGF or EGF that are by themselves insufficient 
gives  an  indication of  the  kind  of  situation in 
which thrombin might be expected to play a role 
in regulating cell proliferation. Although normal 
vascular endothelium represents a  slowly  renew- 
ing cell  population  in  vivo,  endothelial cell  re- 
generation can be triggered by a variety of stimuli, 
especially intimal denudation, which is frequently 
followed by thrombus formation. The contents of 
secretory  granules  are  released  from  platelets 
while, simultaneously, high, localized concentra- 
tions  of  thrombin  are  generated.  The  growth 
factors released from platelets (1, 27), along with 
growth factors normally present in plasma such as 
EGF (4, 22), could act in concert with thrombin 
to  stimulate  regeneration  of  the  endothelium. 
Because these factors may be mitogenic for many 
cell types, an intriguing fail-safe mechanism could 
be provided if the growth factors were present in 
subsaturating concentrations and were active only 
in the  presence of the  high transient concentra- 
tions of thrombin found in such situations. 
Because the continuity of the vascular endothe- 
lium is essential for the growth and survival of the 
organism, the elucidation of the factors involved 
in  endothelial  cell  survival and  proliferation  is 
important. The  development of  endothelial cell 
lines  is  one  of  the  first  steps  toward  such  an 
understanding,  but there are practical implications 
which extend beyond the  development of these 
cell lines. Until now, endothelial cell cultures have 
been developed primarily to  study  the  complex 
functions of these cells, such as the transport of 
high and low density lipoproteins, the production 
and secretion of plasma protein, and that of the 
components of the basal lamina (for review, see 
reference 11). The presence of hormone receptor 
sites and the responsiveness of endothelial cells to 
different hormones (11)  have  also  been investi- 
gated.  One would expect that studies done with 
cell populations maintained in inadequate tissue 
culture  conditions which  give  rise  to  senescent 
populations would lead to misleading conclusions 
as to what the  cells  are  really capable of doing. 
The elucidation of the functions and mechanisms 
through  which  endothelial  cells  achieve  these 
functions can only be achieved by first establishing 
the natural requirements for survival and prolifer- 
ation of this cell type. These requirements are best 
reflected by long-term maintenance of endothelial 
cells at low density as well as by high mitotic index 
of the cultures. Such cell lines should provide an 
adequate  model to study the  metabolic function 
of the vascular endothelium. 
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